1. antagonist expression and / or function mkRNK-29 for use in the prevention and / or treatment of aortic aneurysm formation mlekopitayuschego.2. The antagonist of Claim. 1, wherein said aortic aneurysm is an abdominal aortic aneurysm (AAA) .3. The antagonist of Claim. 1, wherein said aortic aneurysm formation, in addition, includes alleviation of arterial vessels and / or tear aorty.4. The antagonist according to any one of claims. 1-3, wherein said aortic aneurysm, in addition, includes the suppression of expression of genes for extracellular matrix proteins such as collagen, elastin, or fibrillin in arterial tissue, such as COL1A1 COL1A2, COL1A3, ELN and / or FBN1.5. The antagonist according to any one of claims. 1-3, wherein said mkRNK-29 is selected from mkRNK-29a-29b and mkRNK mkRNK-29C, in particular mkRNK-29b.6. The antagonist according to any one of claims. 1-3, wherein said antagonist is selected from antisense DNA and / or RNA-oligonucleotides, antisense 2-O-metiloligoribonukleotidov, antisense oligonucleotides containing phosphorothioate linkages, antisense oligonucleotides containing base closed LNA® nucleic acid antisense morpholino oligonucleotides, agonists PPAR-gamma, and antagomirov smesey.7. The antagonist according to any one of claims. 1-3, wherein said antagonist is administered into the arterial tissue through the stent releasing drug or via ballona.8. A method of detecting an antagonist mkRNK-29a-c, comprising: (a) contacting the cell with a candidate compound (b) evaluation of the activity or expression of at least one of mkRNK-29a-c and (c) comparing the activity or expression in step (b) with the activity or expression mkRNK-29a-c in the absence of the candidate compound, wherein a reduction in activity measurement1. Антагонист экспрессии и/или функционирования мкРНК-29 для применения в профилактике и/или лечении формирования аневризмы аорты у млекопитающего.2. Антагонист по п. 1, где указанная аневризма аорты является аневризмой брюшной
